Ioxitalamic Acid

Summary

Ioxitalamic Acid (CHEMBL2107239) is an approved small-molecule radioopaque medium (ATC V08AA05).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08AA05
• Chemistry: 643.94 Da · C12H11I3N2O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107239
Name	Ioxitalamic Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	34536
ChEBI	CHEBI:83517
ATC	V08AA05
Molecular formula	C12H11I3N2O5
Molecular weight	643.94
InChIKey	OLAOYPRJVHUHCF-UHFFFAOYSA-N

SMILES: CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)C(=O)NCCO)I

IUPAC name: 3-acetamido-5-(2-hydroxyethylcarbamoyl)-2,4,6-triiodobenzoic acid

ChEBI definition: An organoiodine compound that is 2,4,6-triiodobenzoic acid substituted by an acetylamino group at position 3 and a (2-hydroxyethyl)carbamoyl group at position 5. It is used as a contrast medium.

Pharmacological roles (ChEBI): radioopaque medium.

Other ChEBI roles (chemical / environmental): xenobiotic, environmental contaminant.

Also known as: Acide ioxitalamique, Acido ioxitalamico, AG 58107, AG-58107, Ioxitalamic acid, Ioxithalamic acid, IOXITALAMIC ACID

Patent coverage: 180 distinct patent families (491 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 466 (95%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).